The European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved a new Opdivo (nivolumab) ...

Any medication that people inject using the subcutaneous route must be a water-soluble, non-irritant drug given in small quantities of up to 2 milliliters. Subcutaneous injections have some ...

Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) ...

Perspective from Carrie Beach, BSN, RN “One of the key factors influencing patient preference for biologic therapy is the route of administration (ie, IV or subcutaneous),” Lucas Grisanti ...

Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

Dr Marjorie Green, head of global clinical development, oncology, at Merck Research Labs, said the subcutaneous route "has the potential to improve the patient experience as well as increase ...

The full analysis confirms the RaniPill ® delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied. "We are delighted to explore the ...

This segment encompasses both intradermal and subcutaneous routes of administration. The significant market share can be attributed to the ease of dermal-based administration, which is less ...

The full analysis confirms the RaniPill delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied. "We are delighted to explore the ...

Helena Yu, MD, discusses the importance of zipalertinib's oral administration route for patients with EGFRm non–small cell lung cancer.